Clinical trial
Study Evaluating Bazedoxifene Dose-Response in Japanese Patients With…
NCT00238745 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00238745 |
|---|---|
| Title | Study Evaluating Bazedoxifene Dose-Response in Japanese Patients With Postmenopausal Osteoporosis. |
| Official title | Bone Mineral Density Increase and Safety of TSE-424 Compared to Placebo in Osteoporotic Postmenopausal Women |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Postmenopausal Osteoporosis |
| Intervention type | Drug |
| Interventions | Bazedoxifene, Placebo |
| Enrollment | 375 |
| Start date | Aug 1, 2003 |
| Completion | Mar 1, 2007 |
| First posted | Oct 13, 2005 |
| Last update posted | Dec 20, 2007 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: